Icon

ZELAPAR (nda021479)- (1.25MG)

SELEGILINE HYDROCHLORIDE BAUSCH
1.25MG
No Yes
2016-Mar-01 Expired
None None
None No
ZELAPAR, a monoamine oxidase type B (MAO-B) inhibitor, is indicated as an adjunct in the management of patients with Parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy.
0 0 0
Total Other Developers None
Drugs with Suitability No
1.25MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.